Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
LINC02525 (Long intergenic non-protein coding RNA 2525) is a long non-coding RNA gene located on chromosome 6p25.2. It is highly expressed in certain cancers, notably neuroblastoma and glioma. Experimental studies demonstrate that LINC02525 can enhance tumor cell migration and invasion, influence cell proliferation, and regulate apoptosis, likely through interaction with cellular proteins such as ribosomal protein RPL35. LINC02525 and related lncRNAs are emerging as important players in cancer progression and are under exploration as potential therapeutic targets and biomarkers in oncology. No classical small molecule or biologic drugs currently target LINC02525 directly, but ongoing research may identify targeted therapies or RNA-based interventions in the future.
Not applicable for classical small molecules; experimental evidence suggests it acts by binding/interacting with specific proteins such as RPL35, influencing gene expression and tumor cell behaviors
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2525 (LINC02525).